Fosun medicine transfers two new drugs of type II diabetes and tumor to sellas

As a leading pharmaceutical listed company in China, Fosun Pharmaceutical has made important progress in R & D and innovation On October 23, 2013, Chongqing fuchuang Pharmaceutical Research Co., Ltd (hereinafter referred to as "Chongqing fuchuang"), a subsidiary of Fosun Pharmaceutical Holding Co., Ltd., and sellas clinical Holding AG (hereinafter referred to as "sellas") formally signed a cooperation agreement in Greece Chongqing fuchuang will transfer its independent research and development of two compounds related to type II diabetes and tumor: fotagliptin to sellas Benzoate (phengliptine benzoate) and pan her inhibitors (Pan her inhibitors) worldwide (except for the Chinese market) development, sales and other rights The transfer price is about 388 million euros (about 3.248 billion yuan), which is paid in installments according to the progress of research and development Chongqing fuchuang will be entitled to a royalty of 10% of the net sales of the two compounds in the relevant region for 8 years after the two compounds have passed the phase III clinical trial and obtained the approval of the United States and / or Europe; meanwhile, it will be entitled to a 3% interest in sellas subsidiary that owns the two compounds Du Qiwen, Chinese ambassador to Greece, notis mitarakis, Deputy Minister of development of the Greek government, Chen Qiyu, chairman of Fosun Pharmaceutical, Wang Wei, CEO and scientist of Chongqing fuchuang, and Dr angelos stergiou, CEO and chairman of sellas Life Sciences Group, attended the signing ceremony in Greece The signing of this cooperation project is of far-reaching significance for Fosun Pharmaceutical, because it is the first time that Fosun Pharmaceutical has gone abroad in the field of research and development, aiming at large indications such as diabetes and cancer, and at the same time, it is the first time that the research and development of patented innovative products has entered the European and American market Du Qiwen, Chinese ambassador to Greece, said: "the Chinese government is very supportive of this scientific and technological innovation and hopes to push the new drug to the market as soon as possible with the joint efforts of both sides At the same time, this will certainly strengthen the bilateral relations between China and Greece." For this cooperation, Chen Qiyu, chairman of Fosun Pharmaceutical, said: "the out licensing transaction shows that Fosun Pharmaceutical's R & D capability is recognized by overseas pharmaceutical enterprises This is a milestone event of Fosun Pharmaceutical internationalization Fosun's international strategy has taken an important step in the international expansion of its products and expanded its influence in the global pharmaceutical industry We are very looking forward to this cooperation, and we are looking forward to working with sellas to accelerate the R & D process, realize the product launch as soon as possible, and benefit the vast number of patients " In recent years, Fosun Pharmaceutical has focused on the core pharmaceutical business, continuously increased investment in scientific research, and established a unique "4 + 1" R & D platform with small molecular chemical innovative drugs, high-difficulty generic drugs, large molecular biological drugs and special preparations as the main research and development direction Chongqing fuchuang is an important platform of Fuxing Pharmaceutical, which focuses on the research and development of molecular compounds, especially for cancer and metabolic diseases, and focuses on the drug research and development stage from the primary research and development stage to the preparatory clinical stage Wang Weibo, CEO of Chongqing fuchuang, is the main R & D scientist of the two innovative drugs and the talent introduced by the "thousand talents plan" of the National Central Organization Department He said: "this cooperation with sellas will speed up the international development of these innovative compounds We are pleased that sellas and we share the same desire to commercialize these innovative drugs for type II diabetes and cancer " Sellas is a global European company developing biopharmaceutical, medical equipment, clinical research and scientific research business It has leading potential in clinical research and development, and has strong research and scientific innovation capabilities Through this cooperation, sellas will not only obtain the relevant rights of the two new drugs under research in the global (except China), but also conduct continuous research and development of clinical trials in Greece and around the world Dr angelos stergiou, CEO and chairman of sellas Life Sciences Group, said: "for our company, being able to cooperate with fuchuang and its parent company, Fosun Pharmaceutical, is not only very helpful for us to develop innovative drugs for type 2 diabetes and cancer, but also a milestone for the company's development Our cooperation with fuchuang will promote the exchange of professional scientific and technological knowledge and innovative R & D activities between Greece and China Our highly experienced management team will make every effort to promote the market position of these molecular drug projects, because it has a huge market of more than 45 billion euros " For a long time, the innovation of Chinese pharmaceutical enterprises has not been recognized by the world In 2007, the state encouraged independent innovation, implemented "major new drug creation", and encouraged more and more pharmaceutical enterprises to think about the future in terms of innovation Fosun medicine adheres to the concept of "continuous innovation, sharing health", adheres to the established development strategy, and practices "internal skill" with vision and hard work In recent years, Fosun Pharmaceutical has invested in the research and development of medicine in domestic pharmaceutical enterprises Last year, the total investment in drug research and development reached 370 million yuan At present, the annual investment in research and development accounts for 7% - 9% of the operating revenue of pharmaceutical business Through the layout, the product line of Fosun medicine is mainly divided into five major disease treatment fields: metabolism, digestive tract, cardiovascular system, anti-tumor, central nervous system and anti infection Fosun Pharmaceutical is constantly enriching and upgrading its product echelon in these fields, and is gradually deepening and penetrating Based on the "4 + 1" R & D platform, Fosun Pharmaceutical also plans to build a Chinese medicine platform in the future Just a week ago, Fosun Pharmaceutical just reached a strategic cooperation with Shanghai University of traditional Chinese medicine, which will jointly carry out research and cooperation in new drug development, platform construction, technology upgrading, personnel training and other related fields Innovation depends on persistence In addition to the huge investment in human resources and capital, Fosun Pharmaceutical also innovatively integrates domestic and foreign resources, actively follows up the global pharmaceutical industry's cutting-edge technology, and constantly enhances the R & D capacity of enterprises Fosun Pharmaceutical has successively cooperated with Handa group of USA and Longsha group of Switzerland to jointly develop the high-tech barrier drugs urgently needed in the Chinese market; Fosun Pharmaceutical Technology Innovation Strategic Alliance, which is composed of famous domestic scientific research institutes, is one of the "industry university research alliance" of major national new drug innovation science and technology projects; Dalian Wanchun has cooperated to establish a joint venture company to jointly develop the drugs with international patent authorization Innovative anti-tumor drugs Based on the continuous enhancement of the company's endogenous R & D strength, Fosun Pharmaceutical makes full use of the existing R & D advantages to accelerate the implementation of innovation strategy On November 20, 2012, Fosun Pharmaceutical cooperated with Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences to jointly develop innovative anti-tumor drugs focusing on three targets The cooperation mode is different from the loose cro mode of the "industry university research alliance" in the past It is co development Both sides share risks, share innovative drug patents, share achievements and profits This private pharmaceutical innovation force cooperates with the innovation ability of the national team, leading Fosun Pharmaceutical to improve its innovation ability in an all-round way At present, the cooperation is progressing rapidly and smoothly After learning that Fosun Pharmaceutical's innovative drugs go abroad, they are jointly developed with international enterprises in the mainstream market Ding Jian, director of Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences, said: "China's biopharmaceutical industry has entered an important strategic transition period relying on independent innovation of science and technology and transformation of growth mode I'm glad to see that Fosun Pharmaceutical has made initial achievements in its investment and persistence in innovation This also proves once again the industrialization resources and new drug R & D ability of Fosun Pharmaceutical We believe that the advantages of Shanghai Pharmaceutical Institute and Fosun Pharmaceutical are complementary, strong and United, and they will soon produce fruitful results Through sincere cooperation between our two sides, we will develop good drugs that Chinese people can afford, so that China's innovative drugs can go more and faster to the world, and better benefit the people It will certainly contribute to the realization of the three-step development plan of China's biomedicine " Mr Chen Qiyu, chairman of Fosun Pharma, pointed out: "Fosun Pharma has been focusing on new business opportunities for a long time As far as I know, our cooperation with sellas is also the first pharmaceutical project between China and Greece This cooperation is Fosun Pharma's exploration of bringing innovation achievements to mainstream innovative pharmaceutical enterprises in Europe and the United States, which means Fosun Pharma The R & D investment for many years has gradually entered the harvest period We firmly believe that under the constant innovation investment, the company's innovation ability will be continuously improved and the innovation achievements will continue to emerge We also have the ability and confidence to push the new drugs independently developed by China out of the country and into the mainstream market in Europe and the United States " (Bio Valley bio Com) · implement a large number of clinical research agreements in the fields of heart disease, virology, hematology, rheumatology, neurology, osteoporosis, etc · develop innovative medical devices in the central nervous system Have an elite representative in the global sales and distribution of insti Kit (an instrument for diagnosing HIV in one minute).